Nancy King to Risk Assessment
This is a "connection" page, showing publications Nancy King has written about Risk Assessment.
Connection Strength
0.297
-
King NM. Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics. 2012; 40(4):823-30.
Score: 0.070
-
King NM, Henderson G. Treatments of last resort: informed consent and the diffusion of new technology. Mercer Law Rev. 1991; 42(3):1007-50.
Score: 0.065
-
King NM. Benefits, harms, and motives in clinical research. Hastings Cent Rep. 2009 Jul-Aug; 39(4):3.
Score: 0.059
-
King NM, Henderson GE, Churchill LR, Davis AM, Hull SC, Nelson DK, Parham-Vetter PC, Rothschild BB, Easter MM, Wilfond BS. Consent forms and the therapeutic misconception: the example of gene transfer research. IRB. 2005 Jan-Feb; 27(1):1-8.
Score: 0.043
-
Churchill LR, Nelson DK, Henderson GE, King NM, Davis AM, Leahey E, Wilfond BS. Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB. 2003 May-Jun; 25(3):1-8.
Score: 0.038
-
Henderson GE, Easter MM, Zimmer C, King NM, Davis AM, Rothschild BB, Churchill LR, Wilfond BS, Nelson DK. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med. 2006 Jan; 62(1):239-53.
Score: 0.011
-
Henderson GE, Davis AM, King NM, Easter MM, Zimmer CR, Rothschild BB, Wilfond BS, Nelson DK, Churchill LR. Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Mol Ther. 2004 Aug; 10(2):225-31.
Score: 0.010